ZOPOLRESTAT (BioDeep_00000004778)
human metabolite blood metabolite Volatile Flavor Compounds
代谢物信息卡片
2-(4-oxo-3-{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl}-3,4-dihydrophthalazin-1-yl)acetic acid
化学式: C19H12F3N3O3S (419.0551438)
中文名称: 唑泊司他
谱图信息:
最多检出来源 Homo sapiens(blood) 33.33%
分子结构信息
SMILES: C1=CC=C2C(=C1)C(=NN(C2=O)CC3=NC4=C(S3)C=CC(=C4)C(F)(F)F)CC(=O)O
InChI: InChI=1S/C19H12F3N3O3S/c20-19(21,22)10-5-6-15-14(7-10)23-16(29-15)9-25-18(28)12-4-2-1-3-11(12)13(24-25)8-17(26)27/h1-7H,8-9H2,(H,26,27)
描述信息
C471 - Enzyme Inhibitor > C72880 - Aldose Reductase Inhibitor
D007004 - Hypoglycemic Agents
D004791 - Enzyme Inhibitors
同义名列表
7 个代谢物同义名
2-(4-oxo-3-{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl}-3,4-dihydrophthalazin-1-yl)acetic acid; 3,4-dihydro-4-oxo-3-((5-(Trifluoromethyl)-2-benzothiazolyl)methyl)-1-phthalazine-acetic acid; 3,4-dihydro-4-oxo-3-((5-Trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetate; ZOPOLRESTAT; CP 73850; Alond; Zopolrestat
数据库引用编号
14 个数据库交叉引用编号
- KEGG: C01865
- KEGGdrug: D02328
- PubChem: 1613
- HMDB: HMDB0260044
- Metlin: METLIN65665
- DrugBank: DB08772
- ChEMBL: CHEMBL10372
- chemspider: 1554
- CAS: 110703-94-1
- PMhub: MS000017374
- PubChem: 4979
- PDB-CCD: ZST
- NIKKAJI: J360.579E
- RefMet: Zopolrestat
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Changxuan Shi, Yuanfang Wang, Jing Gao, Si Chen, Xiangqian Zhao, Chengchao Cai, Chang Guo, Longxin Qiu. Inhibition of aldose reductase ameliorates alcoholic liver disease by activating AMPK and modulating oxidative stress and inflammatory cytokines.
Molecular medicine reports.
2017 Sep; 16(3):2767-2772. doi:
10.3892/mmr.2017.6895. [PMID: 28677809] - Longxin Qiu, Chengchao Cai, Xiangqian Zhao, Yan Fang, Weibiao Tang, Chang Guo. Inhibition of aldose reductase ameliorates ethanol‑induced steatosis in HepG2 cells.
Molecular medicine reports.
2017 May; 15(5):2732-2736. doi:
10.3892/mmr.2017.6313. [PMID: 28447762] - Tong Chen, Duanyu Shi, Jinfeng Chen, Yanxue Yang, Mengguang Qiu, Wei Wang, Longxin Qiu. Inhibition of aldose reductase ameliorates diet-induced nonalcoholic steatohepatitis in mice via modulating the phosphorylation of hepatic peroxisome proliferator-activated receptor α.
Molecular medicine reports.
2015 Jan; 11(1):303-8. doi:
10.3892/mmr.2014.2713. [PMID: 25333350] - Dina Badawy, Hany M El-Bassossy, Ahmed Fahmy, Ahmad Azhar. Aldose reductase inhibitors zopolrestat and ferulic acid alleviate hypertension associated with diabetes: effect on vascular reactivity.
Canadian journal of physiology and pharmacology.
2013 Feb; 91(2):101-7. doi:
10.1139/cjpp-2012-0232. [PMID: 23458193] - Longxin Qiu, Jianhui Lin, Fangui Xu, Yuehong Gao, Cuilin Zhang, Ying Liu, Yu Luo, James Y Yang. Inhibition of aldose reductase activates hepatic peroxisome proliferator-activated receptor-α and ameliorates hepatosteatosis in diabetic db/db mice.
Experimental diabetes research.
2012; 2012(?):789730. doi:
10.1155/2012/789730. [PMID: 22110479] - Gregory M Preston, Roberto A Calle. Elevated Serum Sorbitol and not Fructose in Type 2 Diabetic Patients.
Biomarker insights.
2010 May; 5(?):33-8. doi:
10.4137/bmi.s4530. [PMID: 20520742] - Matthew E Bourcier, Aaron I Vinik. A 41-year-old man with polyarthritis and severe autonomic neuropathy.
Therapeutics and clinical risk management.
2008 Aug; 4(4):837-42. doi:
10.2147/tcrm.s2712. [PMID: 19209266] - Longxin Qiu, Xiaochun Wu, Jenny F L Chau, Irene Y Y Szeto, Wing Yip Tam, Zongsheng Guo, Sookja K Chung, Peter J Oates, Stephen S M Chung, James Y Yang. Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasis.
The Journal of biological chemistry.
2008 Jun; 283(25):17175-83. doi:
10.1074/jbc.m801791200. [PMID: 18445591] - Yu-Jung Chen, Jing Li, John Quilley. Deficient renal 20-HETE release in the diabetic rat is not the result of oxidative stress.
American journal of physiology. Heart and circulatory physiology.
2008 May; 294(5):H2305-12. doi:
10.1152/ajpheart.00868.2007. [PMID: 18326808] - Vinicius F Carvalho, Emiliano O Barreto, Magda F Serra, Renato S B Cordeiro, Marco A Martins, Zuleica Bruno Fortes, Patrícia M R e Silva. Aldose reductase inhibitor zopolrestat restores allergic hyporesponsiveness in alloxan-diabetic rats.
European journal of pharmacology.
2006 Nov; 549(1-3):173-8. doi:
10.1016/j.ejphar.2006.08.037. [PMID: 16979157] - Banavara L Mylari, Sandra J Armento, David A Beebe, Edward L Conn, James B Coutcher, Michael S Dina, Melissa T O'Gorman, Michael C Linhares, William H Martin, Peter J Oates, David A Tess, Gregory J Withbroe, William J Zembrowski. A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.
Journal of medicinal chemistry.
2005 Oct; 48(20):6326-39. doi:
10.1021/jm050462t. [PMID: 16190759] - Satish K Srivastava, Kota V Ramana, Aruni Bhatnagar. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options.
Endocrine reviews.
2005 May; 26(3):380-92. doi:
10.1210/er.2004-0028. [PMID: 15814847] - Qinghong Dan, Rachel Wong, Sookja K Chung, Stephen S M Chung, Karen S L Lam. Interaction between the polyol pathway and non-enzymatic glycation on aortic smooth muscle cell migration and monocyte adhesion.
Life sciences.
2004 Dec; 76(4):445-59. doi:
10.1016/j.lfs.2004.09.010. [PMID: 15530506] - Qinghong Dan, Rachel L C Wong, Shinan Yin, Sookja K Chung, Stephen S M Chung, Karen S L Lam. Interaction between the polyol pathway and non-enzymatic glycation on mesangial cell gene expression.
Nephron. Experimental nephrology.
2004; 98(3):e89-99. doi:
10.1159/000080684. [PMID: 15528949] - Banavara L Mylari, Sandra J Armento, David A Beebe, Edward L Conn, James B Coutcher, Michael S Dina, Melissa T O'Gorman, Michael C Linhares, William H Martin, Peter J Oates, David A Tess, Gregory J Withbroe, William J Zembrowski. A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.
Journal of medicinal chemistry.
2003 Jun; 46(12):2283-6. doi:
10.1021/jm034065z. [PMID: 12773033] - Ioannis Nicolaou, Vassilis J Demopoulos. Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.
Journal of medicinal chemistry.
2003 Jan; 46(3):417-26. doi:
10.1021/jm0209477. [PMID: 12540241] - H L Rittner, V Hafner, P A Klimiuk, L I Szweda, J J Goronzy, C M Weyand. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis.
The Journal of clinical investigation.
1999 Apr; 103(7):1007-13. doi:
10.1172/jci4711. [PMID: 10194473] - R P Schneider, H G Fouda, P B Inskeep. Tissue distribution and biotransformation of zopolrestat, an aldose reductase inhibitor, in rats.
Drug metabolism and disposition: the biological fate of chemicals.
1998 Nov; 26(11):1149-59. doi:
. [PMID: 9806959] - R P Schneider, C J Davenport, K A Hoffmaster, P B Inskeep. Bioavailability, multiple-dose pharmacokinetics, and biotransformation of the aldose reductase inhibitor zopolrestat in dogs.
Drug metabolism and disposition: the biological fate of chemicals.
1998 Nov; 26(11):1160-6. doi:
. [PMID: 9806960] - T Kotani, Y Nagaki, A Ishii, Y Konishi, H Yago, S Suehiro, N Okukado, K Okamoto. Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
Journal of medicinal chemistry.
1997 Feb; 40(5):684-94. doi:
10.1021/jm960594+. [PMID: 9057855] - P B Inskeep, R A Ronfeld, M J Peterson, N Gerber. Pharmacokinetics of the aldose reductase inhibitor, zopolrestat, in humans.
Journal of clinical pharmacology.
1994 Jul; 34(7):760-6. doi:
10.1002/j.1552-4604.1994.tb02037.x. [PMID: 7929871] - R G Tilton, K Chang, K S Hasan, S R Smith, J M Petrash, T P Misko, W M Moore, M G Currie, J A Corbett, M L McDaniel. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation.
Diabetes.
1993 Feb; 42(2):221-32. doi:
10.2337/diab.42.2.221. [PMID: 7678825] - P B Inskeep, A E Reed, R A Ronfeld. Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats.
Pharmaceutical research.
1991 Dec; 8(12):1511-5. doi:
10.1023/a:1015894300247. [PMID: 1808615] - B L Mylari, E R Larson, T A Beyer, W J Zembrowski, C E Aldinger, M F Dee, T W Siegel, D H Singleton. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
Journal of medicinal chemistry.
1991 Jan; 34(1):108-22. doi:
10.1021/jm00105a018. [PMID: 1899452]